SCHEMBL4470561

SCHEMBL4470561

CNC(=O)c1cc(Oc2cccc(-c3c[nH]c(C(=O)N(OC)c4ccc(OC)c(OC(F)(F)F)c4)c3)c2)ccn1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAF1 P04049 9/20 0.43
EPHX2 P34913 1/20 0.43
BRAF P15056 12/20 0.42
RET P07949 2/20 0.39
KDR P35968 4/20 0.39
CSF1R P07333 1/20 0.39
PLK4 O00444 1/20 0.39
AURKA O14965 1/20 0.39
MAPK13 O15264 1/20 0.39
JAK2 O60674 1/20 0.39
MAP4K4 O95819 1/20 0.39
ABL1 P00519 1/20 0.39
LCK P06239 1/20 0.39
FYN P06241 1/20 0.39
LYN P07948 1/20 0.39
ROS1 P08922 1/20 0.39
SRC P12931 1/20 0.39
RPS6KB1 P23443 1/20 0.39
EPHA2 P29317 1/20 0.39
TYK2 P29597 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4476011 0.88 RET (0.43) RAF1EPHX2BRAFRETKDR
SCHEMBL4463488 0.86 KDR (0.50) RAF1EPHX2BRAFRETKDR
SCHEMBL4463607 0.84 BRAF (0.41) RAF1EPHX2BRAFRETKDR
SCHEMBL4470556 0.83 RAF1 (0.49) RAF1EPHX2BRAFRETKDR
SCHEMBL4469834 0.80 KDR (0.54) RAF1EPHX2BRAFRETKDR
SCHEMBL4463609 0.80 RAF1 (0.51) RAF1EPHX2BRAFRETKDR
SCHEMBL4463483 0.78 RAF1 (0.64) RAF1BRAFRETKDRPLK4
SCHEMBL4469341 0.77 BRAF (0.56) RAF1EPHX2BRAFRETKDR
SCHEMBL4480053 0.76 RET (0.57) RAF1EPHX2BRAFRETKDR
SCHEMBL4470287 0.76 KDR (0.50) RAF1EPHX2BRAFRETKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7598274-B2 N-methyl-4-{4-[5-(4-chloro-3-trifluoromethylphenylcarbamoyl)-1H-pyrrol-3-yl]-phenoxy}pyridine-2-carboxamide; Raf kinases inhibitors MERCK PATENT GMBH (DE) 2009-10-06 US claimed
US-20070149594-A1 Pyrrole derivatives MERCK PATENT GMBH (DE) 2007-06-28 US claimed
US-7598274-B2 N-methyl-4-{4-[5-(4-chloro-3-trifluoromethylphenylcarbamoyl)-1H-pyrrol-3-yl]-phenoxy}pyridine-2-carboxamide; Raf kinases inhibitors MERCK PATENT GMBH (DE) 2009-10-06 US disclosed
US-20070149594-A1 Pyrrole derivatives MERCK PATENT GMBH (DE) 2007-06-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070149594-A1 Pyrrole derivatives RAF1, BRAF, ARAF RAF1 1/4885EPHX2 2963/4885BRAF 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.